Eisai Co

Eisai Co FCF Yield

The Free Cash Flow Yield of Eisai Co (4523.T) as of Oct 29, 2026 is 3.30 %. In the previous year, Free Cash Flow Yield was 1.30 % — a change of 152.77% (higher).

FCF Yield

3.30 %

YoY

152.77%

Last updated:

Free Cash Flow Yield of Eisai Co is 2026 3.30 % . Free Cash Flow Yield of Eisai Co was 2025 1.30 % . It decreases by 152.77% higher compared to the previous year.

The Eisai Co FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2019
6.14 JPY
Jan 1, 2020
3.77 JPY
Jan 1, 2021
2.56 JPY
Jan 1, 2022
5.53 JPY
Jan 1, 2023
-2.61 JPY
Jan 1, 2024
2.99 JPY
Jan 1, 2025
1.30 JPY
Jan 1, 2026
3.30 JPY
The Eisai Co FCF Yield history
YEARFCF YieldYoY
3.30 %+152.77%
1.30 %-56.36%
2.99 %-214.70%
-2.61 %-147.11%
5.53 %+115.98%
2.56 %-32.06%
3.77 %-38.56%
6.14 %-38.52%
9.98 %+104.55%
4.88 %-23.40%
6.37 %+37.60%
4.63 %-21.97%
5.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Eisai Co Stock analysis

What does Eisai Co do? Eisai Co Ltd is a Japanese pharmaceutical company based in Tokyo that specializes in research, development, production, and marketing of pharmaceuticals. The company was founded in 1936 by Shinjiro Torii, who had previously worked as a chemist at another pharmaceutical company. Eisai began its journey in the production of medicines, especially herbal medicine known in Japan, which are sold as OTC products. Eisai grew rapidly and started producing antibiotics in 1947. Over the following decades, the company expanded into the global market and is now present in over 20 countries. Eisai is dedicated to creating innovations as its main business model in order to help patients worldwide through its range of products. With this mission, the company has developed and introduced hundreds of drugs to the market, improving the quality of life for millions of people around the world. The company is divided into several business segments, including neurology, oncology, coagulation disorders, and gastrointestinal diseases. Eisai specializes in developing innovative drugs targeting a wide range of human diseases. Eisai is particularly known today for its leading position in Alzheimer's and dementia research. An important milestone in the company's history was the discovery of Aricept, a medication used to treat Alzheimer's disease. Eisai was the first Japanese company to develop a drug approved by the US FDA. Other products from Eisai include Lenvima, a medication for the treatment of thyroid cancer, and Lusedra, a sedative for anesthesia induction and maintenance for patients undergoing surgery. Eisai invests significantly in research and development to maintain its position as an innovation leader in the pharmaceutical manufacturing industry. The company collaborates with leading academic institutions and research organizations to make groundbreaking discoveries in various medical fields. Eisai also places importance on social responsibility and is involved in numerous social projects such as supporting Japan against cancer and providing consultation for elderly home care. The company aims to contribute to making the healthcare system more sustainable and equitable. Overall, Eisai is a leading pharmaceutical company with a strong focus on creating innovations to improve human health. It has a wide range of products and continuously works on developing new drugs and therapies to help patients worldwide. Eisai Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Eisai Co stock

Free Cash Flow Yield of Eisai Co is 3.30 % in 2026.

Free Cash Flow Yield of Eisai Co changed from 1.30 % to 3.30 %, representing a 152.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Eisai Co since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Eisai Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Eisai Co

All Key Metrics — Eisai Co